480 related articles for article (PubMed ID: 21917557)
1. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
4. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
5. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
[TBL] [Abstract][Full Text] [Related]
7. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
Cziraky MJ; Willey VJ; McKenney JM; Kamat SA; Fisher MD; Guyton JR; Jacobson TA; Davidson MH
J Clin Lipidol; 2013; 7(2):102-8. PubMed ID: 23415428
[TBL] [Abstract][Full Text] [Related]
8. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
9. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
10. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
[TBL] [Abstract][Full Text] [Related]
11. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Oldemeyer JB; Lund RJ; Koch M; Meares AJ; Dunlay R
Cardiology; 2000; 94(2):127-8. PubMed ID: 11173785
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for statin-associated rhabdomyolysis.
Schech S; Graham D; Staffa J; Andrade SE; La Grenade L; Burgess M; Blough D; Stergachis A; Chan KA; Platt R; Shatin D
Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):352-8. PubMed ID: 16892458
[TBL] [Abstract][Full Text] [Related]
14. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
Nichols GA; Koro CE
Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias.
Suh HS; Hay JW; Johnson KA; Doctor JN
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):470-84. PubMed ID: 22461130
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
17. Statin-fibrate combination for mixed dyslipidaemia: a limited option?
Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP
Curr Med Res Opin; 2010 Sep; 26(9):2137-40. PubMed ID: 20662560
[TBL] [Abstract][Full Text] [Related]
18. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
20. [Rhabdomyolysis secondary to simvastatin and phenofibrate].
Forcadell-Peris MJ; de Diego-Cabanes C
Semergen; 2014; 40(4):e91-4. PubMed ID: 24768027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]